Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Camostat
2. Camostat Mesilate
3. Camostate
4. Camostate-mesilate
5. Foipan
6. Foy 305
7. Foy S 980
8. Foy-305
9. Foypan
10. N,n-dimethylcarbamoylmethyl-4-(4-guanidinobenzoyloxy)phenylacetate Methanesulfonate
11. P-guanidinobenzoic Acid, Ester With (p-hydroxyphenyl)acetic Acid, Ester With N,n-dimethylglycolamide
1. Camostat Mesilate
2. 59721-29-8
3. Camostat (mesylate)
4. Camostat Methanesulfonate
5. Foipan
6. Camostate
7. Mfcd00941410
8. Foy305
9. Camostat Mesilate [jan]
10. Camostat Mesilate;foy305;foy-s980
11. Dsstox_cid_238
12. 4-(2-(2-(dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate Methanesulfonate
13. Dsstox_rid_75452
14. Dsstox_gsid_20238
15. Chembl85164
16. 2-(dimethylamino)-2-oxoethyl 4-(4-guanidinobenzoyloxy)phenylacetate Methanesulphonate
17. Methanesulfonic Acid 4-{2-[(dimethylcarbamoyl)methoxy]-2-oxoethyl}phenyl 4-carbamimidamidobenzoate
18. 451m50a1eq
19. Cas-59721-29-8
20. Ncgc00167526-01
21. Foy-305
22. Foipan (tn)
23. Camostat Mesylate- Bio-x
24. Camostat Mesilate (jp17)
25. Mls006010697
26. Schembl871583
27. Foy-s980
28. Camostat Mesilate (foy-305)
29. Dtxsid0020238
30. Chebi:31347
31. Amy8832
32. Camostat Mesilate [mart.]
33. Hms3651d04
34. Camostat Mesilate [who-dd]
35. Bcp06708
36. Ex-a4154
37. Tox21_112523
38. Camostat Mesylate, >=98% (hplc)
39. S2874
40. Camostat Methanesulfonate [mi]
41. Akos015966692
42. Akos026750463
43. Tox21_112523_1
44. Ac-8540
45. Ccg-269652
46. Hs-0060
47. Ncgc00167526-02
48. 4-(2-(2-(dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-((diaminomethylene)amino)benzoate Methanesulfonate
49. 4-[[4-[(aminoiminomethyl)amino]benzoyl]oxy]benzeneacetic Acid 2-(dimethylamino)-2-oxoethyl Ester Methanesulfonate
50. Bc164270
51. Hy-13512
52. Smr002530343
53. Sy060177
54. Db-072684
55. B2082
56. Ft-0648873
57. Sw219517-1
58. D01766
59. F20649
60. 721c298
61. A832436
62. Q-200778
63. Q23731028
64. 4-(2-(2-(dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl4-guanidinobenzoatemethanesulfonate
65. 4-(2-{[2-(dimethylamino)-2-oxoethyl]oxy}-2-oxoethyl)phenyl 4-{[amino(imino)methyl]amino}benzoate Methanesulfonate
66. 4-{2-[(dimethylcarbamoyl)methoxy]-2-oxoethyl}phenyl 4-[(diaminomethylidene)amino]benzoate; Methanesulfonic Acid
Molecular Weight | 494.5 g/mol |
---|---|
Molecular Formula | C21H26N4O8S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 494.14713497 g/mol |
Monoisotopic Mass | 494.14713497 g/mol |
Topological Polar Surface Area | 200 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 695 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Trypsin Inhibitors
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (See all compounds classified as Trypsin Inhibitors.)
Protease Inhibitors
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Camostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Camostat manufacturer or Camostat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Camostat manufacturer or Camostat supplier.
PharmaCompass also assists you with knowing the Camostat API Price utilized in the formulation of products. Camostat API Price is not always fixed or binding as the Camostat Price is obtained through a variety of data sources. The Camostat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A camostat mesilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of camostat mesilate, including repackagers and relabelers. The FDA regulates camostat mesilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. camostat mesilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of camostat mesilate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A camostat mesilate supplier is an individual or a company that provides camostat mesilate active pharmaceutical ingredient (API) or camostat mesilate finished formulations upon request. The camostat mesilate suppliers may include camostat mesilate API manufacturers, exporters, distributors and traders.
click here to find a list of camostat mesilate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The camostat mesilate Drug Master File in Japan (camostat mesilate JDMF) empowers camostat mesilate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the camostat mesilate JDMF during the approval evaluation for pharmaceutical products. At the time of camostat mesilate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of camostat mesilate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a camostat mesilate Drug Master File in Korea (camostat mesilate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of camostat mesilate. The MFDS reviews the camostat mesilate KDMF as part of the drug registration process and uses the information provided in the camostat mesilate KDMF to evaluate the safety and efficacy of the drug.
After submitting a camostat mesilate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their camostat mesilate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of camostat mesilate suppliers with KDMF on PharmaCompass.
A camostat mesilate written confirmation (camostat mesilate WC) is an official document issued by a regulatory agency to a camostat mesilate manufacturer, verifying that the manufacturing facility of a camostat mesilate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting camostat mesilate APIs or camostat mesilate finished pharmaceutical products to another nation, regulatory agencies frequently require a camostat mesilate WC (written confirmation) as part of the regulatory process.
click here to find a list of camostat mesilate suppliers with Written Confirmation (WC) on PharmaCompass.
camostat mesilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of camostat mesilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right camostat mesilate GMP manufacturer or camostat mesilate GMP API supplier for your needs.
A camostat mesilate CoA (Certificate of Analysis) is a formal document that attests to camostat mesilate's compliance with camostat mesilate specifications and serves as a tool for batch-level quality control.
camostat mesilate CoA mostly includes findings from lab analyses of a specific batch. For each camostat mesilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
camostat mesilate may be tested according to a variety of international standards, such as European Pharmacopoeia (camostat mesilate EP), camostat mesilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (camostat mesilate USP).